For: | Yang X, Peng P, Zhang L. Multiline treatment of advanced squamous cell carcinoma of the lung: A case report and review of the literature. World J Clin Cases 2019; 7(14): 1899-1907 [PMID: 31417937 DOI: 10.12998/wjcc.v7.i14.1899] |
---|---|
URL: | https://www.wjgnet.com/2307-8960/full/v7/i14/1899.htm |
Number | Citing Articles |
1 |
|
2 |
Chen Yang, Rui Zeng, Yawen Zha, Yani Li, Ting Wang, Ruolan Zhao, Minying Li, Jingjing Zhang. Case report: Clinical complete response in advanced ALK-positive lung squamous cell carcinoma: a case study of successful anti-PD-1 immunotherapy post ALK-TKIs failure. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1360671
|
3 |
Bin Yao, Xue Han, Linrong Pang, Caihong Xu, Sisi Liu, Xiaochun Cheng, Jun Chen. Acquired ALK Resistance Mutations Identified from Liquid Biopsy in an ALK-Rearranged Squamous Cell Lung Cancer Patient Treated with Sequential ALK TKI Therapy: A Case Report. OncoTargets and Therapy 2021; : 4329 doi: 10.2147/OTT.S315832
|
4 |
Hong Shu, Zhi-jian Ren, Hui Li, Yao Zhang, Ci Yin, Fang Nie. Ultrasound-mediated nanobubbles loaded with STAT6 siRNA inhibit TGF-β1-EMT axis in LUSC cells via overcoming the polarization of M2-TAMs. European Journal of Pharmaceutical Sciences 2024; 202: 106894 doi: 10.1016/j.ejps.2024.106894
|
5 |
Denggang Fu, Biyu Zhang, Lei Yang, Shaoxin Huang, Wang Xin. Development of an Immune-Related Risk Signature for Predicting Prognosis in Lung Squamous Cell Carcinoma. Frontiers in Genetics 2020; 11 doi: 10.3389/fgene.2020.00978
|